financetom
Business
financetom
/
Business
/
Activist investor Politan files lawsuit against medical device maker Masimo
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Activist investor Politan files lawsuit against medical device maker Masimo
Jul 17, 2024 3:25 PM

July 17 (Reuters) - Activist investor Politan Capital

has filed a lawsuit against medical device maker Masimo Corp ( MASI )

, seeking to have the company hold its annual meeting as

soon as possible.

In the lawsuit, filed in a Delaware court, Politan also

sought a declaration that Masimo ( MASI ) will not reject Politan's

nominees to the board.

Politan has a near 9% stake in Masimo ( MASI ) and has nominated

two candidates to be elected to the company's five-member board.

Only two board seats will be voted on this year.

On Tuesday, Masimo ( MASI ) postponed its annual shareholder

meeting to Sept. 19 from July 25, drawing criticism from

Politan, which called it a "last-gasp attempt" to prevent

shareholder voices from being heard.

Politan's legal action comes a day after Masimo ( MASI ) filed a

lawsuit against Politan, seeking to force the activist investor

to correct "material misstatements and omissions" in its proxy

materials.

Quentin Koffey-owned Politan has long criticized

Masimo's ( MASI ) capital allocation and board oversight and expressed

concerns about the California-based company's $1 billion

purchase of consumer audio products maker Sound United.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
China to study facilitating cross-border data flows for connected vehicles, state media says
China to study facilitating cross-border data flows for connected vehicles, state media says
Oct 17, 2024
BEIJING, Oct 17 (Reuters) - China will boost cooperation with other countries in standards and regulation, and study policies to facilitate cross-border data flows, its industry minister said on Thursday when outlining the future for connected vehicles, according to state media. Jin Zhuanglong made the remarks at the opening of an intelligent connected vehicle conference in Beijing where he vowed...
Nokia Q3: Earnings Miss, CEO Cites Telecom Weakness And Anticipates India Demand Rebound
Nokia Q3: Earnings Miss, CEO Cites Telecom Weakness And Anticipates India Demand Rebound
Oct 17, 2024
Nokia Corp  reported a fiscal third-quarter net sales decline of 8% year-on-year (7% in constant currency) to 4.33 billion euros ($4.76 billion), missing the analyst consensus estimate of $5.34 billion. The comparable EPS was $0.07 (0.06 euros), compared to the analyst consensus estimate of $0.08. The stock slid after the quarterly print. Also Read: Ericsson Q3 Earnings: Gains From AT&T Boost, CEO Signals North...
Uranium Energy Receives Regulatory Approval for Wyoming Plant Production Expansion
Uranium Energy Receives Regulatory Approval for Wyoming Plant Production Expansion
Oct 17, 2024
07:49 AM EDT, 10/17/2024 (MT Newswires) -- Uranium Energy ( UEC ) said Thursday it secured the Wyoming Department of Environmental Quality's approval to expand the licensed production capacity at its Irigaray Central Processing Plant to 4 million pounds of Triuranium octoxide, a uranium compound, annually. The company said Stantec agreed to offer its services to support production expansion at...
Amicus Therapeutics Settles Patent Suit Against Teva Pharmaceuticals with License Agreement
Amicus Therapeutics Settles Patent Suit Against Teva Pharmaceuticals with License Agreement
Oct 17, 2024
07:50 AM EDT, 10/17/2024 (MT Newswires) -- Amicus Therapeutics ( FOLD ) said Thursday that it agreed to grant Teva Pharmaceuticals (TEVA) a license to market its generic version of Amicus' treatment Galafold in the US starting in early 2037, as a settlement for a patent litigation against Teva. Amicus previously filed a complaint relating to Teva's abbreviated new drug...
Copyright 2023-2026 - www.financetom.com All Rights Reserved